agonists and antagonists (see below), has been more recently enriched by the isolation and cloning of T K receptors from mammalian tissues (see [6] for review).
The first generation of T K antagonists, developed at the beginning of the 1980s by insertion of u-Trp residues in the sequence of SP [7] , yielded a first generation of antagonists which have enabled the transmitter role of SP to be established. However, such antagonists (the prototype of which is Spantide) suffer from a number of drawbacks including low potency, partial-agonist activity, limited ability to discriminate between NK-1 and NK-2 receptors, neurotoxicity after intrathecal administration, local anaesthetic activity, induction of mast-cell degranulation and ability to antagonize peptides unrelated to the T K family [8] .
In the past few years, a second generation of peptidic T K antagonists has been developed [9-14, Table 11 . These new tools have the advantage of a greater potency and marked selectivity for only one of the three T K receptors. The improved profile also includes, at least for some examples, specificity in blocking TKs action as compared with unrelated peptides (e.g. bombesin), lack of local anaesthetic Table I The three generations of TK antagonists Guinea-p'g bronchi Hamster urinary bladder Guinea-pig renal pelvis
Rat colon* Guinea-pig gallbladder Rat urinary bladder* Human ileum (circular muscle) Rat vas deferens* Human colon (circular muscle) Rat ileum and colon* Bovine urinary bladder Human bronchi? Bovine stomach *Denotes that in these preparations the affinity of R 396 for (see Table 3) findings: (' ) the different affinity Of NK-2receptor- Examples of preparations which, on the basis of the above criteria, contain NK-2A or NK-2R receptors are listed in Table 2 . Until now, the expression of the two subtypes in preparations of the same species has not been established. Therefore the possibility that the two 'subtypes' represent a speciesrelated variation of the same receptor may not be excluded. Preliminary observations suggest the NK-2 receptor mediating contraction of the human isolated bronchi fulfills some of the criteria proposed for identification of the NK-2R subtype (low affinity of MEN antagonists, MDI, 28564 inactive as an agonist), while the circular muscle of the human colon and ileum seem to express NK-2A
Santicioli, unpublished work). This topic is under intense investigation in many laboratories and the above mentioned classification should be viewed more as a working hypothesis than as a firm conclusion. It is also possible that more than two subtypes of the NK-2 receptor exist in mammalian tissues. For example R39b discriminates with high (hamster preparations), intermediate (rat preparations) and low affinity (cow, rabbit and guinea-pig preparations) between NK-2 receptors expressed in smooth muscles from different species, causing the possibility of further heterogeneity (Table 3) .
Recently, preliminary evidence for the existence of multiple forms of NK-1 receptor has been obtained as well. The potency of CP 96345 in displacing radiolabelled SP from brain membrane preparations is markedly species-dependent: CP 96 345 is 100-500-fold more potent at NK-1 receptors in bovine, guinea-pig or rabbit brain than in rat, afferents which are widely distributed to both the visceral and somatic areas. These primary afferents signal to the central nervous system a noxious event generated in the periphery (sensory function), and also play an 'efferent' function determined by transmitter(s) release in the periphery (e.g. neurogenic inflammation in the airways and urinary tract) [21, 221. In the gut, TKs are also expressed by a population(s) of intrinsic neurons and participate in the regulation of motility [23] . Endogenous TKs are released by a variety of stimulants and depolarizing agents in the periphery, and this event has been recognized as potentially important for the genesis of various human diseases including bronchial asthma, urinary incontinence, hypermotility of the gut and inflammatory diseases of joints and viscera. Therefore, the development of potent and selective TK-receptor antagonists represents a promising approach for therapy of a variety of human diseases.
Crucial to this point is the knowledge of the receptor types which are expressed by target cells present in human tissues. The latter information is ant species-related variations exist in the receptor types or subtypes which mediate the same function (e.g. smooth-muscle contraction) in the same organ of different species, or in different organs of the same species. The following is a description of the possible uses of NK-1-or NK-2-receptor antagonists in various diseases at peripheral level with emphasis to the visceral territory.
In the respiratory tract, TKs exert a variety of actions (bronchoconstriction, increase in vascular permeability, stimulation of mucus secretion) that may contribute to genesis and symptoms of asthma/bronchial hyper reactivity. Hronchoconstriction is mediated by different TK receptors in different species, and by NK-2 receptors in the human isolated bronchi [24] . The other effects seem largely mediated through NK-1 receptors [24] . Thus an NK-2-receptor antagonist could be viewed as a new type of anti-bronchospastic agent, while NK-1 antagonists could find a place in treatment of the chronic inflammation of the airways which underlies bronchial hyper-reactivity.
In the urinary tract TKs are powerful spasmogens: in this case both NK-1 and NK-2 receptors mediate the same response (e.g. bladder contraction) in different species, but only NK-2 receptors mediate this effect in the human bladder (as well as in the human urethra and ureter) [25] . By contrast, NK-1 receptors mediate the inflammatory effects of TKs in the urinary tract [25] . An NK-2-receptor antagonist could be used to reduce motility of the urinary bladder while an NK-1 -receptor antagonist could be considered for treatment of any inflammatory condition of the urinary tract having a neurogenic component.
Similar considerations also apply to the gastrointestinal tract. At this level TKs, released from intramural enteric neurons, participate in intestinal peristalsis and the TK-mediated component becomes more and more important for high intensities of stimulation [26] . In the circular muscle of both the human ileum [27] and colon, NK-2 receptors mediate TK-induced contraction, and a T K antagonist could be used to control exaggerated intestinal motility. An NK-1 -receptor antagonist could be useful for treatment of certain chronic inflammatory diseases of the gut (e.g. Crohn's disease).
T o summarize, NK-2-receptor antagonists could represent a new generation of drugs useful for the control of spasms at visceral level, while NK-1 -receptor antagonists could prove useful for different types of visceral inflammatory diseases.
I
NK-1-receptor antagonists could also be considered as anti-inflammatory agents at somatic level with possible application to acute and chronic inflammations of the skin and joints.
